I will just reiterate, because I very much support that same position. We have seen that it's not the intellectual property that has slowed the availability of the vaccines across the globe; it has been the complexity of the supply chain and the distribution of it.
As we see across all manufacturers, the partnership in the ecosystems that we've created to be able to get the medicine to the local level has really been key to our success.